MedPath

Oleclumab

Generic Name
Oleclumab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1803176-05-7
Unique Ingredient Identifier
5CRY01URYQ
Background

Oleclumab is under investigation in clinical trial NCT03819465 (A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC).

Associated Conditions
-
Associated Therapies
-
medicalxpress.com
·

Clinical trial: Combining durvalumab with novel agents increases pathological responses in ...

The NeoCOAST-2 study showed durvalumab combined with Dato-DXd achieved the highest pathological complete response rates among tested regimens for resectable NSCLC, with Arm 4 yielding a 34.1% pCR rate and a favorable safety profile.
onclive.com
·

Novel Perioperative Combinations Show Efficacy in Resectable NSCLC

NeoCOAST-2 trial showed high pathologic complete response (pCR) and major pathologic response (mPR) rates in resectable NSCLC patients treated with novel combinations, with Dato-DXd plus durvalumab and single-agent platinum chemotherapy achieving the highest pCR (34.1%) and mPR (65.9%) rates. All arms demonstrated manageable safety profiles and comparable surgical rates.
aacrjournals.org
·

A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
© Copyright 2025. All Rights Reserved by MedPath